Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations

A Ghezzi, B Banwell, A Bar-Or… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …
被引用次数：29 相关文章

Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations

A Ghezzi, B Banwell, A Bar-Or… - Multiple sclerosis …, 2021 - pubmed.ncbi.nlm.nih.gov
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …

Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations

A Ghezzi, B Banwell, A Bar-Or, T Chitnis… - MULTIPLE …, 2020 - research.unipd.it
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …

Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations

A Ghezzi, B Banwell, A Bar-Or, T Chitnis… - Multiple Sclerosis …, 2021 - diva-portal.org
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …

Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.

A Ghezzi, B Banwell, A Bar-Or… - Multiple Sclerosis …, 2021 - search.ebscohost.com
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …

Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.

A Ghezzi, B Banwell, A Bar-Or, T Chitnis… - Multiple Sclerosis …, 2020 - europepmc.org
Anti-CD20 therapies have established efficacy in the treatment of immune-mediated
neurological and non-neurological diseases. Rituximab, one of the first B-cell-directed …